Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Gains from Investment Securities: 2022-2025

Historic Gains from Investment Securities for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Jun 2025 value amounting to -$2.0 million.

  • Corvus Pharmaceuticals' Gains from Investment Securities fell 10.79% to -$2.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$26.6 million, marking a year-over-year change of. This contributed to the annual value of $33.4 million for FY2024, which is 3225.19% up from last year.
  • According to the latest figures from Q2 2025, Corvus Pharmaceuticals' Gains from Investment Securities is -$2.0 million, which was up 91.99% from -$25.1 million recorded in Q1 2025.
  • Corvus Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $2.3 million during Q4 2024, with a 5-year trough of -$25.1 million in Q1 2025.
  • Its 3-year average for Gains from Investment Securities is -$2.7 million, with a median of $400,000 in 2024.
  • In the last 5 years, Corvus Pharmaceuticals' Gains from Investment Securities spiked by 328.31% in 2024 and then plummeted by 6,382.25% in 2025.
  • Corvus Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at -$985,000 in 2022, then decreased by 4.37% to -$1.0 million in 2023, then soared by 328.31% to $2.3 million in 2024, then dropped by 10.79% to -$2.0 million in 2025.
  • Its last three reported values are -$2.0 million in Q2 2025, -$25.1 million for Q1 2025, and $2.3 million during Q4 2024.